989 Results
Schizophrenia
Learn more about schizophrenia, including symptoms, risk factors, treatment options, and answers to your questions.
Advocacy Update: November/December 2024
Learn more about November/December 2024 Advocacy Update at psychiatry.org
Advocacy Issues
Learn about advocacy issues related to telepsychiatry in APA@s Telepsychiatry Toolkit.
APA Member Benefit: One-Time Immigration Attorney Consultation
To support International Medical Graduates members, help them navigate their immigration related questions, APA has established a one-time, 30-45 minute consultation opportunity with leading immigration attorneys at no cost to APA members.
Clinical Practice Guidelines
APA practice guidelines provide evidence-based recommendations for the assessment and treatment of psychiatric disorders.
Tobacco and Nicotine
Learn about various aspects of treating tobacco use disorders, including clinical, training, and policy considerations. As new topics emerge, more resources and information will be added to this page. The resources covers topics from the APA Work Group on Tobacco Use Disorders with the Council on Addiction Psychiatry, training, practice/clinical, reimbursement and legal issues from leading psychiatrists.
Mental Health Equity Looking Beyond Series
Continuation of the APA Fireside Chats discussions where strategies and opportunities to improve the mental health of historically marginalized and minoritized communities were examined. The APA Looking Beyond Series will bring an interdisciplinary lens to the discussion, leveraging innovative frameworks to address mental health inequities.
International
APA is a global hub for the exchange of experiences and knowledge in the field of psychiatry and mental health.
Health Insurance Coverage & Access to Care
As policymakers continue to debate health care reform proposals, APA is committed to legislative solutions that ensure benefits, coverage, medication, and access to substance use disorder treatment.
Medicare Part D
This federal outpatient prescription drug benefit, which began in 2006, applies to all Medicare beneficiaries, including those who are dually eligible for both Medicare and Medicaid.